Invitrocue signs technology development agreement to include indications for multiple breast cancer subtypes.

– Invitrocue to develop new breast cancer models for Onco-PDO TM that will include leading breast cancer subtypes ER+, PR+, HER2+ and Triple Negative Breast Cancer

January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco- PDOTM test.

Under the agreement, Professor Arial Zeng, an expert in stem cells during mammary development and breast cancer, will help Invitrocue to develop and optimise the protocols for the in vitro culture, propagation and expansion of patient-derived organoids (PDOs) from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC.

The IP will be jointly owned by both parties and Invitrocue will be granted global commercialisation rights to any intellectual property (IP) developed under the agreement.

Commenting on the collaboration, Dr. Steven Fang, Executive Chairman, Invitrocue, said:

“Whilst we already offer breast cancer testing with Onco-PDOTM, this collaboration agreement is an important advancement of our technology to expand into multiple subtypes of the world’s leading cancer for women. Professor Arial Zeng is a world-renowned scientist in breast cancer organoid biology, and we look forward to working closely with her. This collaboration will enable us to provide even more precise and personalised data for breast cancer patients, leveraging our evidence-based approach to inform treatment pathways and improve patient outcomes.”

About Invitrocue Ltd 

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field ofoncology. Invitrocue’s Onco-PDOTM technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research(A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

InvitroCue Limited │ ACN 009 366 009
Level 2, 350 Kent Street, Sydney, NSW, 2000, Australia

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website:


SIBCB is a leading research institute for life sciences in China, focusing on human health and the frontiers of biology, and dedicated to pursuing research excellence.


Media  Contact:

Martin D. Bach, VP Operations

T: +65 6460 0497